Adding topiramate to valproate therapy may cause reversible hepatic failure

Epileptic Disorders

Volumn 5, Issue 3, 2003, Pages 157-159

  Bumb, Anja ^a   Diederich, Nico ^a   Beyenburg, Stefan ^a,b,c  

^a Neurosciences Department   (Luxembourg)

^b UNIVERSITY OF BONN   (Germany)

^c CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

Author keywords

Adverse effects; Combination therapy; Epilepsy; Liver failure; Topiramate; Valproate

Indexed keywords

ANTICONVULSIVE AGENT; TOPIRAMATE; VALPROIC ACID;

ADULT; ARTICLE; DRUG TOLERABILITY; EPILEPSY; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; LIVER FAILURE; LIVER TOXICITY; PRIORITY JOURNAL; RISK FACTOR; SYMPTOM;

ANTICONVULSANTS; DRUG THERAPY, COMBINATION; EPILEPSIES, PARTIAL; FEMALE; FRUCTOSE; HEPATITIS, TOXIC; HUMANS; INTRACRANIAL ANEURYSM; LIVER FUNCTION TESTS; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; VALPROIC ACID;

EID: 0344013535     PISSN: 12949361     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Sachedo RC. Topiramate. Clinical profile in epilepsy. Clin Pharmacokinet 1998; 34: 335-46.
2. Hamer HM, Knake S, Schomburg U, et al. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology 2000; 54: 230-2.
3. Longin E, Teich M, Koelfen W, et al. Topiramate enhances the risk of valproate-associated side effects in three children. Epilepsia 2002; 43: 451-4.
4. Bjoro K, Gjerstad L, Bentdal O, et al. Topiramate and fulminant liver failure. Lancet 1998; 352: 11-9.
5. Mack CJ, Kuc S, Mulcrone SA, et al. Interaction of topiramate with carbamazepine: two case reports and a review of clinical experience. Seizure 2002; 11: 464-7.
6. Hachad H, Ragueneau-Majlessi I, Levy RH. New antiepileptic drugs: review on drug interactions. Ther Drug Monit 2002; 24: 91-103.